EUCTR2009-015410-22-DE进行中(未招募)不适用
A multicenter, randomized, double-blind study with 2 groups as prove of concept for the treatment of ACE induced angioedema with subcutaneous Icatibant - AMACE
Medizinische Fakultaet der Technischen Universitaet Muenchen0 个研究点目标入组 30 人开始时间: 2010年2月3日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中(未招募)
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Age ³ 18 years<96 years
- •Patient is currently treated with an ACEI
- •Patient must have acute angioedema attack caused by an ACEI
- •Treatment should be administrated within 10 hrs after onset by an ACEI
- •Patient with angioedema of head and /or neck (face, lips, cheeks, tongue, soft palate/uvula, pharynx and larynx)
- •At least one moderate to severe severe angioedema symptom as assessed by the investigator, requiring a medical intervention
- •Signed written Informed Consent Form
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Diagnosis of angioedema that was not caused by ACEI: e.g. hereditary angioedema (C1-INH deficiency), allergy, anaphylaxis, insect bite, trauma, infection, abscess, local tumor, post-radiation or post-operative or processes related to salivary glands and others where it is unlikely that the ACEI is causing the angioedema
- •Participation in a clinical trial of another investigational medicinal product (IMP) within 30 days
- •Patients with acute urticaria
- •Patients with a medical history of any angioedema before taking an ACEI
- •Patients with an acute rash or hives in the face or somewhere else
- •Unstable angina or acute myocardial infarction
- •Acute heart failure
- •Serious concomitant illnesses that the physician considers to be a contraindication for participation in the trial
- •Pregnancy and/or breast-feeding
- •Mental condition rendering the patients, in the opinion of the investigator, unable to understand the nature, scope and possible consequences of the study;
- •Unlikely to comply with the protocol, e.g., uncooperative attitude, inability to return for the follow-up visit, or unlikely to complete the study for any reason.
- •akte heart disease NYHA-Clssification 3-4
研究者
相似试验
进行中(未招募)
不适用
A double-blind, randomized, multi-center study with 500 mg QD of TRO19622 versus placebo in patients with painful peripheral diabetic neuropathyEUCTR2006-004545-42-LVTROPHOS180
进行中(未招募)
不适用
A double-blind, randomized, multi-center study with 500 mg QD of TRO19622 versus placebo in patients with painful peripheral diabetic neuropathyEUCTR2006-004545-42-DETROPHOS180
进行中(未招募)
不适用
A study of RoActemra/Actemra (tocilizumab) in combination with methotrexate in patients with rheumatoid arthritis with inadequate response to prior treatment with methotrexate and low disease activity with the combination de RoActemra/Actemra y methotrexate.MedDRA version: 14.0Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid arthritisEUCTR2011-001626-15-ESRoche Farma, S.A.
进行中(未招募)
不适用
A multi-center, randomized, double-blind study to evaluate the efficacy and long-term safety of vildagliptin modified release (MR) as add-on therapy to metformin in patients with type 2 diabetesEUCTR2008-004722-16-GBovartis Pharma Services AG2,500
已完成
2 期
A study to evaluate the effictiveness and safety of Vildagliptin in Subjects With Type 2 Diabetes.CTRI/2009/091/000134ovartis Healthcare Private Limited452
